EUVIMEDEUVIMED entdecken
Crossref

BRAF V600E /p-ERK/p-DRP1(Ser616) Promotes Tumor Progression and Reprogramming of Glucose Metabolism in Papillary Thyroid Cancer

Shi-Shuai Wen, Yi-Jun Wu iD, Jia-Yang Wang, Zhao-Xian Ni, Shuai Dong, Xiao-Jun Xie, Yu-Ting Wang, Yu Wang, Nai-Si Huang, Qing-Hai Ji, Ben Ma, Ning Qu

Thyroid® · 2024-10 · 34 (10) · 1246-1259

DOI: 10.1089/thy.2023.0700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, online erschienen am 20.08.2024. Verfasst von Shi-Shuai Wen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R. China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Thyroid Cancer, Papillary, Thyroid Neoplasms, Dynamins. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Papillary thyroid cancer (PTC) with the BRAF V600E mutation is associated with a poorer prognosis. BRAF inhibitors may demonstrate limited efficacy due to emerging drug resistance. The Warburg effect may have cancer therapeutic implications. It is not known if the BRAF V600E mutation is associated with altered glucose metabolism in PTC.

Methods

This study examined the effect of BRAF V600E and dynamin-related protein 1 (DRP1) on various cellular processes in PTC cells, including cell proliferation, migration, invasion, mitochondrial fission, glucose metabolism, reactive oxygen species (ROS) generation, and apoptosis. We used RT-qPCR to assess the expression of key glycolytic enzymes in thyroid cancer tissues. Additionally, the regulatory interaction between BRAF V600E and DRP1 was investigated through Western blot and immunohistochemical staining. We further evaluated the impact of DRP1 in PTC and the inhibitory effects of dabrafenib and 2-deoxy- d -glucose (2-DG) in vitro and in vivo .

Results

We found that the BRAF V600E mutation significantly augments aerobic glycolysis while suppressing oxidative phosphorylation in PTC. We identified the BRAF V600E /p-ERK/p-DRP1(Ser616) signaling pathway as a critical mediator in PTC progression. First, the BRAF V600E /p-ERK/p-DRP1(Ser616) signaling pathway enhances cell proliferation by upregulating hexokinase 2 expression and thereby increasing aerobic glycolysis. Second, it inhibits apoptosis by promoting mitochondrial fission and reducing ROS levels. Moreover, we demonstrated that the combination therapy of 2-DG and dabrafenib markedly impedes the progression of BRAF V600E -positive PTC.

Conclusion

The BRAF V600E /p-ERK/p-DRP1(Ser616) signaling pathway plays a pivotal role in glucose metabolism reprogramming, contributing to the aggressiveness and progression of BRAF V600E -positive PTC. Our findings suggest that a combined therapeutic approach using 2-DG and dabrafenib has the potential to improve the outcome of PTC patients with BRAF V600E .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafThyroid Cancer, PapillaryThyroid NeoplasmsDynaminsGlucoseCell ProliferationHumansCell Line, TumorDisease ProgressionAnimalsGlycolysisApoptosisMiceMutationCell MovementFemale

Stichwörter der Autor:innen

2-DGBRAFV600EDRP1glucose metabolismpapillary thyroid cancer

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanDNM1L protein, humanDynaminsGlucose

Autor:innen und Institutionen

  • Department of Thyroid Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R. China.
  • Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
  • Department of Plastic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, P.R. China.

ORCID-Profile: Yi-Jun Wu

Zitieren

APA

Wen, S. S., Wu, Y. J., Wang, J. Y., Ni, Z. X., Dong, S., Xie, X. J., Wang, Y. T., Wang, Y., Huang, N. S., Ji, Q. H., Ma, B., & Qu, N. (2024). BRAF V600E /p-ERK/p-DRP1(Ser616) Promotes Tumor Progression and Reprogramming of Glucose Metabolism in Papillary Thyroid Cancer. Thyroid®, 34(10), 1246-1259. https://doi.org/10.1089/thy.2023.0700

Vancouver

Wen SS, Wu YJ, Wang JY, Ni ZX, Dong S, Xie XJ, et al. BRAF V600E /p-ERK/p-DRP1(Ser616) Promotes Tumor Progression and Reprogramming of Glucose Metabolism in Papillary Thyroid Cancer. Thyroid®. 2024;34(10):1246-1259. doi:10.1089/thy.2023.0700

BibTeX
@article{Wen2024,
  author = {Wen, Shi-Shuai and Wu, Yi-Jun and Wang, Jia-Yang and Ni, Zhao-Xian and Dong, Shuai and Xie, Xiao-Jun and Wang, Yu-Ting and Wang, Yu and Huang, Nai-Si and Ji, Qing-Hai and Ma, Ben and Qu, Ning},
  title = {BRAF V600E /p-ERK/p-DRP1(Ser616) Promotes Tumor Progression and Reprogramming of Glucose Metabolism in Papillary Thyroid Cancer},
  journal = {Thyroid®},
  year = {2024},
  volume = {34},
  number = {10},
  pages = {1246--1259},
  doi = {10.1089/thy.2023.0700}
}
Kostenlos starten →